Please login to the form below

Not currently logged in
Email:
Password:

RPSGB warns pharmacists about cough and cold medicines

The Royal Pharmaceutical Society of Great Britain has told pharmacists that they have two years to prove that they can properly control the sales of certain cough and cold medicines
The Royal Pharmaceutical Society of Great Britain (RPSGB) has told pharmacists that they have two years to prove that they can properly control the sales of certain cough and cold medicines.

In 2008 the Medicines and Healthcare products Regulatory Agency (MHRA) said that products containing pseudoephedrine/ephedrine should be legally reclassified as prescription-only medicines (POM). According to the RPSGB, the two components can be used to manufacture crystal methamphetamine (crystal meth), and the process is relatively simple for anyone with medical knowledge.

Community pharmacists have been issued with guidance from the RPSGB on how best to control the sales of medicines containing pseudoephedrine/ephedrine. The measures include increasing staff awareness of the problem, keeping medicines behind the counter and limiting the amount a consumer can purchase in a single visit.

David Pruce, director of practice and quality improvement for the society, said: "Continued vigilance and improving staff awareness of the issues relating to pseudoephedrine/ephedrine misuse may help demonstrate that supply of these products can confidently be managed within the pharmacy setting. These medicines are used to treat coughs and colds so there is a naturally high demand and it is important that pharmacists continue to balance this with consumer safety."

The MHRA stated that if evidence emerges that the illegal manufacture of crystal meth has not been contained, then pseudoephedrine/ephedrine should reclassified as POM in July 2009. The society hopes that allowing pharmacies two years to prove they can control sales of the drugs sends a clear signal of faith in the profession to consumers.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics